Goldman Sachs
GS
$881.26
-1.12%
Goldman Sachs is a global investment bank founded in 1869 whose core franchises span investment banking advisory and underwriting, global markets sales and trading, asset and wealth management, and a small, shrinking consumer lending book; it operates across every major financial center in the world. The firm is the preeminent M&A advisor by revenue for two decades running and functions as a bellwether for capital-markets activity rather than a plain-vanilla lender, with roughly 30% of post-provision revenue now coming from more predictable fee-based asset and wealth management. The current investor debate centers on whether the capital-markets supercycle — evidenced by a Q3 2026 beat driven by a 72% surge in equities revenues and robust investment banking — can persist against a backdrop of rising bond yields, higher-for-longer rates, and a sharp rotation out of speculative AI trades that has pressured financials and growth stocks alike. Bulls point to the pending Anthropic IPO, where Goldman is a lead advisor, as a fee windfall and a signal of a reopened new-issue window, while bears argue the stock's 17% three-month drawdown reflects peak-cycle earnings and a market that has already priced in the best of the advisory and trading boom.…
GS
Goldman Sachs
$881.26
Related headlines
Investment Opinion: Should I buy GS Today?
The synthesized recommendation is Hold. The core thesis is that Goldman Sachs is a high-quality franchise with strong fundamentals and an attractive forward valuation, but the current downtrend and cyclical earnings risk warrant caution until a bottom forms. The analyst consensus rating of 'hold' (mean 2.54) and average target price of $1,037.90 (17.8% upside) support a neutral stance, suggesting the stock is fairly valued after the recent drawdown.
Supporting evidence includes the 22.91% YoY revenue growth in Q2 2026, a net margin of 17.25% (up from 11.91%), and a forward PE of 12.01x, which is below the sector average. The PEG ratio of 0.65 indicates the stock is cheap relative to growth, and the 1.92% dividend yield with a 30.7% payout ratio is sustainable. However, the stock trades at a premium on trailing metrics (16.92x PE, 2.20x P/B) and has significantly underperformed the market (-17.27% vs. +2.69% for SPY over three months).
The biggest risks are a cyclical earnings rollover, high leverage (debt-to-equity 4.88x), and negative free cash flow. The rating would upgrade to Buy if the stock stabilizes above $950 and forward EPS estimates hold, or if the Anthropic IPO and other capital-markets activity drive stronger-than-expected Q4 results. It would downgrade to Sell if revenue growth decelerates below 10% or if the stock breaks below the $850 support level. Relative to its history and peers, the stock appears fairly valued to slightly undervalued on a forward basis, but the premium trailing multiple and cyclical peak earnings limit upside until clarity emerges.
Sign up to view all
GS 12-Month Price Forecast
The forward-looking view is balanced. On one hand, Goldman Sachs is a premier franchise trading at a discount on forward earnings, with strong revenue growth and profitability. On the other hand, the stock is in a clear downtrend, has underperformed the market significantly, and faces cyclical earnings risk. The analyst consensus is neutral, and the wide target range reflects genuine uncertainty. I would upgrade to bullish if the stock stabilizes above $950 and forward estimates hold, or if capital-markets activity accelerates. I would downgrade to bearish if revenue growth decelerates below 10% or if the stock breaks below $850.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Goldman Sachs's 12-month outlook, with a consensus price target around $1037.90 and implied upside of +17.8% versus the current price.
Average Target
$1037.90
0 analysts
Implied Upside
+17.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$730 - $1250
Analyst target range
Coverage is broad, with 21 analysts and a consensus recommendation of 'hold' (mean rating 2.54 on a 1–5 scale where lower is more bullish), and an average target price of $1,037.90 — implying +17.8% upside from the current $881.26. The consensus is therefore neutral-to-cautiously-optimistic: analysts see value after the drawdown but are not pounding the table, and the recent rating actions confirm that stance, with HSBC maintaining Hold (upgraded from Reduce in July), Wells Fargo at Overweight, Citigroup and UBS at Neutral, BMO and KBW at Market Perform, and BofA and Evercore at Buy/Outperform. The pattern is one of stable-to-mildly-positive revisions rather than a wave of upgrades, suggesting the Street is waiting for evidence that the Q3 beat is repeatable before turning more constructive.
The target range is unusually wide — from a low of $730.00 (about 17% below the current price) to a high of $1,250.00 (about 42% above) — a spread of roughly 71% of the current price that signals genuine disagreement about the cycle. The high target likely assumes multiple expansion back toward 2.5x P/B and sustained capital-markets activity, including IPO fee windfalls such as the Anthropic listing; the low target prices in a sharp revenue normalization, margin compression from rising compensation ratios, and a higher-for-longer rate environment that suppresses dealmaking. Consensus 2026 EPS of $84.15 (range $76.84–$88.28) and revenue of $79.9 billion (range $74.6–$82.9 billion) bracket a relatively tight fundamental forecast, meaning the dispersion in price targets is driven more by multiple assumptions than by earnings uncertainty — a setup where sentiment, not fundamentals, will determine the next leg.
Drowning in data?
Find the real signal!
Bulls vs Bears: GS Investment Factors
The bear case currently has stronger evidence due to the stock's sharp 17.27% three-month decline, relative underperformance of -19.96% versus SPY, and failure to rally on a strong Q3 earnings beat. However, the bull case is supported by accelerating fundamentals (22.91% revenue growth, 17.25% net margin) and an attractive forward valuation (12.01x forward PE, PEG 0.65). The single most important tension is whether the capital-markets supercycle can be sustained; if it can, the stock is undervalued, but if earnings roll over, the premium multiple and high leverage could amplify downside. The market is currently pricing skepticism, as evidenced by the 23.7% drawdown from the July high.
Bullish
- Earnings growth accelerating sharply: Q2 2026 revenue grew 22.91% YoY to $38.43B, and net income more than doubled to $6.63B from $3.72B, lifting net margin to 17.25% from 11.91%. The Q3 2026 beat, driven by a 72% surge in equities revenues, confirms the momentum is continuing.
- Attractive forward valuation: The stock trades at 16.92x trailing earnings but only 12.01x forward earnings, a 29% compression that implies the market expects strong EPS growth. The PEG ratio of 0.65 suggests the stock is cheap relative to its expected growth.
- Analyst target implies upside: The average analyst target price of $1,037.90 represents 17.8% upside from the current $881.26, with a high target of $1,250 (42% upside). The consensus recommendation is 'hold' (mean 2.54), but the target range skews positive.
- Anthropic IPO fee windfall: Goldman is a lead advisor on the pending Anthropic IPO, expected in October, which could generate substantial advisory fees and signal a reopened new-issue window. This is a concrete catalyst that could boost investment banking revenues in Q4 2026 and beyond.
Bearish
- Severe relative underperformance: GS has fallen 17.27% over three months versus a 2.69% gain in SPY, a relative strength of -19.96. Year-to-date, the stock is down 3.62% while SPY is up 11.93%, a -15.55% relative gap, indicating a clear downtrend and loss of momentum.
- Peak-cycle earnings risk: The 72% equities revenue surge and record trading volumes may represent cyclical peaks. If capital-markets activity normalizes, revenue and margins could compress sharply, especially given the 4.88x debt-to-equity and negative free cash flow of -$41.5B.
- High leverage and negative cash flow: Debt-to-equity of 4.88x and a current ratio of 0.83 reflect a liability-heavy balance sheet. Trailing free cash flow is deeply negative at -$41.5B, and the negative PCF ratio of -6.09 means cash generation is episodic and dependent on market-making flows.
- Valuation premium to peers: At 16.92x trailing PE and 2.20x P/B, GS trades at the higher end of the bulge-bracket range (peers at 12-16x PE and 1.5-2.0x P/B). This premium may not be justified if ROE (13.74%) is only mid-pack versus its own history.
GS Technical Analysis
Goldman Sachs is in a clear intermediate-term downtrend despite a still-positive one-year return of +16.25%, a divergence that tells the story: the stock made its 52-week high of $1,153.99 in mid-July 2026 and has since fallen to $881.26, which places it at just 34.1% of its 52-week range (low $740.01, high $1,153.99) — closer to the bottom than the top. That positioning means the stock is no longer a momentum vehicle but a potential value candidate, though the phrase 'falling knife' applies until a base forms, given the price is 23.6% below its high, essentially matching the reported max drawdown of -23.73%. The trend structure is lower highs and lower lows since July, with the 50-day and 200-day averages almost certainly now sloping down and acting as overhead supply.
Short-term momentum is decisively negative and accelerating on the downside: the stock is -6.05% over the past month and -17.27% over three months, versus a +1.22% and +2.69% move in SPY over the same windows, producing relative strength of -7.27 and -19.96 respectively — a stark underperformance that has widened as the year progressed (YTD -3.62% vs. SPY +11.93%, a -15.55% relative gap). The 1-month decline is smaller than the 3-month decline, hinting the pace of selling may be decelerating, but the most recent sessions (from $891.28 on Oct 15 to $881.26 on Oct 16, -1.12%) show no confirmed reversal, and the stock has printed a sequence of lower closes through October ($900.36 on Sep 30 to $878.72 on Oct 14). Notably, the Oct 13 Q3 earnings beat — with a 72% equities revenue surge — failed to produce a durable rally, a classic sign of 'sell the news' behavior and distribution into strength.
Key technical levels are well defined: support sits at the 52-week low of $740.01, roughly 16% below the current $881.26, while resistance is the July high of $1,153.99, about 31% above. A decisive break below the $880–$900 shelf (which has held for several sessions) would likely open a test of the $850 area and eventually the $740 low, signaling that the market is pricing a cyclical earnings rollover; conversely, reclaiming the $950–$1,000 zone would be the first evidence of a bottom. With a beta of 1.284, Goldman is roughly 28% more volatile than the market, meaning a 10% SPY drawdown could translate to a ~13% hit here — position sizing should account for that amplified downside, and the elevated short ratio of 3.2 days-to-cover suggests short sellers are not yet crowded, leaving room for further pressure.
Beta
1.28
1.28x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$743-$1154
Price range past year
Annual Return
+16.2%
Cumulative gain past year
| Period | GS Return | S&P 500 |
|---|---|---|
| 1m | -6.0% | +0.2% |
| 3m | -17.3% | +2.9% |
| 6m | -4.8% | +8.4% |
| 1y | +16.2% | +14.9% |
| ytd | -3.6% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GS Fundamental Analysis
Revenue momentum is genuinely strong: Q2 2026 revenue of $38.43 billion grew 22.91% year-over-year versus $31.27 billion in Q2 2025, and the sequential progression from $17.23 billion (Q1 2026) to $38.43 billion (Q2 2026) reflects the seasonal strength of the capital-markets calendar plus a powerful trading environment. The segment mix shows Global Markets at $20.63 billion and Investment Management at $9.22 billion, confirming that trading and advisory — the cyclical, market-sensitive engines — are carrying the load, which cuts both ways: it explains the 72% equities revenue surge cited in the Q3 beat but also exposes results to any volatility contraction. The multi-quarter trend is one of acceleration (Q2 2025 revenue $31.27B, Q3 2025 $32.15B, Q4 2025 $30.13B, Q1 2026 $17.23B, Q2 2026 $38.43B), and consensus 2026 revenue of ~$79.9 billion implies the Street expects the run-rate to hold, making the durability of trading revenues the single most important variable for the investment case.
Profitability is robust and expanding: Q2 2026 net income was $6.63 billion on a 17.25% net margin, up sharply from $3.72 billion and an 11.91% margin in Q2 2025, while gross margin improved to 52.66% from 45.41% a year earlier and operating margin reached 29.99% versus 15.86%. The quarterly net margin trajectory — 11.91% (Q2 2025), 12.74% (Q3 2025), 15.33% (Q4 2025), 32.68% (Q1 2026), 17.25% (Q2 2026) — shows meaningful year-over-year expansion even as the Q1 figure was flattered by a favorable mix, and the 47.48% gross margin and 17.47% operating margin in the valuation dataset corroborate a business operating near cyclical peak efficiency. For an investment bank, a ~17% net margin and ~30% operating margin are strong but not unprecedented, and the key risk is that compensation and non-compensation expenses normalize upward as revenue cools, compressing margins faster than the top line declines.
Balance-sheet leverage is the defining risk: debt-to-equity stands at 4.88x (with total-debt-to-capitalization of 85.8% and long-term debt at 74.5% of capitalization), a current ratio of 0.83 signals a liability-heavy funding structure typical of broker-dealers, and trailing free cash flow is deeply negative at -$41.5 billion, reflecting the working-capital and inventory swings inherent to market-making. ROE of 13.74% and ROA of just 1.11% illustrate the thin-spread, high-turnover economics of the model, while the negative PCF ratio of -6.09 and FCF per share of -$53.75 in Q4 2025 confirm that cash generation is episodic and balance-sheet-driven rather than smooth. The company funds itself through wholesale financing and deposit-like liabilities rather than internal cash flow, so the 1.92% dividend yield (payout ratio 30.7%) and multi-billion buybacks ($4.0 billion repurchased in Q2 2026) are sustainable only as long as capital-markets revenues and funding access hold — a genuine tail risk if credit spreads widen.
Quarterly Revenue
$38.4B
2026-06
Revenue YoY Growth
+22.9%
YoY Comparison
Gross Margin
52.7%
Latest Quarter
Free Cash Flow
$-41.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GS Overvalued?
Because Goldman is solidly profitable (Q2 2026 net income of $6.63 billion; trailing EPS positive), the PE ratio is the appropriate primary metric, and the stock trades at 16.92x trailing earnings against a forward PE of 12.01x — a 29% compression that implies the market expects earnings to grow meaningfully into 2027, consistent with consensus EPS of $84.15 versus the current run-rate. The PEG ratio of 0.65 suggests the stock is cheap relative to its expected growth, and the 2.20x P/B and 2.20x P/S sit alongside an EV/Sales of 1.53x and an EV/EBITDA of 29.96x, the latter inflated by the low EBITDA base typical of banks. The wide trailing-to-forward PE gap is the crux of the debate: it either signals a genuine value opportunity or reflects skepticism that peak-cycle earnings can be sustained.
Against the capital-markets peer group, Goldman's 16.92x trailing PE and 2.20x P/B are at the higher end of the bulge-bracket range (Morgan Stanley and JPMorgan typically trade in the 12–16x PE and 1.5–2.0x P/B bands), implying a modest premium that is arguably justified by its leading M&A franchise and superior ROE relative to peers — though the 13.74% ROE is only mid-pack versus its own history. The 12.01x forward PE is the more compelling comparison: if consensus EPS of $84.15 is achieved, the stock would trade at a discount to the sector on a forward basis, which is why the PEG of 0.65 screens attractively. The 1.92% dividend yield is below the sector average, reflecting Goldman's preference for buybacks over income, and the negative PCF ratio means cash-flow-based valuation is not meaningful here.
Historically, Goldman's PE has ranged from roughly 8.6x (Q1 2024) to 25.8x (Q2 2023) over the past several years, with the current 16.92x sitting near the middle-to-upper portion of that band, while the P/B of 2.20x is near the top of its 0.87x–2.47x historical range (the Q2 2026 reading of 2.47x was the cycle high). That positioning suggests the market is pricing in optimistic but not euphoric expectations — the multiple has already de-rated from its July peak alongside the 23.7% drawdown, which partially de-risks the valuation. If earnings hold and the multiple merely mean-reverts to its 5-year average, the stock has room to recover; if earnings roll over, the current multiple offers limited downside cushion given the historical trough PE of ~8.6x.
PE
16.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 6x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
30.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant due to Goldman's high leverage and cyclical revenue base. Debt-to-equity stands at 4.88x, with total-debt-to-capitalization at 85.8%, and a current ratio of 0.83 indicates a liability-heavy funding structure. Trailing free cash flow is deeply negative at -$41.5B, reflecting the working-capital swings inherent to market-making, and the negative PCF ratio of -6.09 means cash generation is episodic. Additionally, revenue is concentrated in Global Markets ($20.63B) and Investment Management ($9.22B), making results highly sensitive to trading volumes and market volatility. A downturn in capital-markets activity could rapidly compress margins, as compensation expenses may not decline as quickly as revenue.
Market and competitive risks include valuation compression and sector rotation. GS trades at 16.92x trailing PE and 2.20x P/B, a premium to peers like Morgan Stanley and JPMorgan (12-16x PE, 1.5-2.0x P/B), which may not be sustainable if growth slows. The stock's beta of 1.284 means it is 28% more volatile than the market, so a 10% SPY drawdown could translate to a ~13% hit. Recent news highlights a rotation out of speculative AI trades and rising bond yields, which could pressure financials. The bond market sell-off and higher-for-longer rates may suppress dealmaking and trading activity, while geopolitical tensions add further uncertainty.
The worst-case scenario involves a sharp normalization in capital-markets activity, leading to a revenue decline and margin compression, compounded by a broader market selloff. In this scenario, the stock could test its 52-week low of $740.01, representing a 16% decline from the current $881.26. The analyst low target of $730.00 implies a 17.2% downside. If earnings fall below the consensus EPS of $84.15 and the multiple compresses toward the historical trough of 8.6x, the stock could fall further, potentially to the $700-$750 range. Given the 23.7% max drawdown already experienced, a total decline of 20-25% from current levels is plausible in a severe downturn.
FAQ
The most severe risk is a cyclical downturn in capital-markets activity, which could cause revenue and earnings to decline sharply, given the 22.91% YoY growth in Q2 2026 may be peak-cycle. Financial risk is elevated with a debt-to-equity of 4.88x and negative free cash flow of -$41.5B, which could strain the balance sheet if funding conditions tighten. Competitive risk includes pressure from peers like Morgan Stanley and JPMorgan, and regulatory headwinds could increase compliance costs. Macro risk is significant with a beta of 1.284, meaning the stock is 28% more volatile than the market, and rising rates could suppress dealmaking. Company-specific risk includes dependence on key personnel and reputational risks.
The 12-month forecast has three scenarios: Bull (25% probability) with a target range of $1,150-$1,250, assuming the capital-markets supercycle persists and the Anthropic IPO boosts fees; Base (50% probability) with a target range of $1,000-$1,050, assuming earnings normalize but remain solid and the stock recovers to the analyst average target; Bear (25% probability) with a target range of $730-$800, assuming a cyclical downturn and multiple compression. The base case is most likely, hinging on consensus EPS of $84.15 being achieved and the forward PE holding around 12x. The wide target range reflects genuine uncertainty about the cycle.
GS appears fairly valued to slightly undervalued on a forward basis. The trailing PE of 16.92x is at the higher end of its peer group (12-16x) and near the middle-to-upper portion of its historical range (8.6x-25.8x), but the forward PE of 12.01x is below the sector average, implying the market expects earnings growth. The PEG ratio of 0.65 indicates the stock is cheap relative to its expected growth rate. The P/B of 2.20x is near the top of its historical range (0.87x-2.47x), suggesting the market is pricing in optimistic but not euphoric expectations. Overall, the valuation is reasonable given the growth outlook, but the premium trailing multiple leaves limited margin of safety if earnings disappoint.
From a risk/reward perspective, GS offers a favorable upside of 17.8% to the average analyst target of $1,037.90, with a forward PE of 12.01x and a PEG of 0.65 suggesting undervaluation. However, the stock is in a downtrend, down 17.27% over three months, and faces cyclical earnings risk with high leverage. The biggest downside risk is a test of the 52-week low of $740.01, representing a 16% decline. For long-term investors with a higher risk tolerance, the current price may be an attractive entry point, but waiting for technical stabilization above $900 or $950 would reduce risk. It is less suitable for short-term traders due to the negative momentum.
GS is more suitable for long-term investment (minimum 2-3 years) given its cyclical nature and the current downtrend. The stock has a beta of 1.284, indicating higher volatility, and its earnings are tied to capital-markets cycles, which can take time to recover. The dividend yield of 1.92% is modest, so total return depends on capital appreciation. Short-term trading is risky due to the negative momentum and lack of a clear bottom. A suggested minimum holding period is 2-3 years to ride out a full cycle, with entry points considered after technical stabilization or on further weakness toward the 52-week low.
